Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI

Inclusion Criteria:Over 19 years oldPatients who agreed to the research protocol and clinical follow-up survey plan, decided to participate in this study voluntarily, and gave written consent to the informed consent form.Patients who underwent percutaneous coronary stenting for acute coronary syndromeExclusion Criteria:Patients who have previously taken statins,Patients with active liver disease or patients with three times or more increase in AST or ALTIf you have an allergic or hypersensitivity reaction to Evorucumab, statin, or Ezetimib,Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this studyThe remaining life expectancy is expected to be less than a year.Subjects who visited the hospital due to psychogenic shock and are expected to be less likely to survive by medical judgmentSubjects participating in a randomized clinical trial of medical devices/pharmaceuticals